Latest & greatest articles for multiple sclerosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on multiple sclerosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on multiple sclerosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for multiple sclerosis

123. Ocrelizumab (Ocrevus Genentech Inc.) for primary progressive and relapsing-remitting multiple sclerosis

Ocrelizumab (Ocrevus Genentech Inc.) for primary progressive and relapsing-remitting multiple sclerosis Ocrelizumab (Ocrevus; Genentech Inc.) for primary progressive and relapsing-remitting multiple sclerosis Ocrelizumab (Ocrevus; Genentech Inc.) for primary progressive and relapsing-remitting multiple sclerosis HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation HAYES, Inc. Ocrelizumab (Ocrevus; Genentech Inc.) for primary progressive and relapsing-remitting multiple sclerosis. Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2017 Authors' conclusions Multiple sclerosis (MS) is an autoimmune disorder that impacts the spinal cord and brain. MS presents in various forms, including relapsing-remitting MS (RRMS) or primary progressive MS (PPMS). Technology Description: Ocrelizumab (Ocrevus) is a humanized monoclonal antibody therapy

2017 Health Technology Assessment (HTA) Database.

124. Ocrelizumab appears to reduce relapse and disability in multiple sclerosis but quality of evidence is moderate

Ocrelizumab appears to reduce relapse and disability in multiple sclerosis but quality of evidence is moderate Ocrelizumab appears to reduce relapse and disability in multiple sclerosis but quality of evidence is moderate | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Ocrelizumab appears to reduce relapse and disability in multiple sclerosis but quality of evidence is moderate Article Text Commentary: General medicine Ocrelizumab

2017 Evidence-Based Medicine

125. Fingolimod (Gilenya) - highly active relapsing remitting multiple sclerosis

Fingolimod (Gilenya) - highly active relapsing remitting multiple sclerosis Final Appraisal Recommendation Advice No: 3516 – December 2016 Fingolimod (Gilenya ® ) 0.5 mg hard capsules Submission by Novartis Pharmaceuticals UK Ltd Additional note(s): • Please refer to the Summary of Product Characteristics for the full licensed indication. In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3135), which (...) in full and cited as: All Wales Medicines Strategy Group Final Appraisal Recommendation – 3516: Fingolimod (Gilenya ® ) 0.5 mg hard capsules December 2016 Recommendation of AWMSG Fingolimod (Gilenya ® ) is recommended as an option for use within NHS Wales for use as a single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following adult patient group: - patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling

2017 All Wales Medicines Strategy Group

126. 29 Year Old Man with Multiple Sclerosis and Schizophrenia: A Case Report Full Text available with Trip Pro

29 Year Old Man with Multiple Sclerosis and Schizophrenia: A Case Report Multiple sclerosis (MS) is the most common debilitating neurological disease that affects adults, whether young adults or middle-aged. Although, most attention is toward the neurological signs of the disease, the neuropsychiatric signs are not uncommon. This case report presents a 29 year old male with a record of obsessive-compulsive disorder (OCD) without psychotic disorder, which coincides with the diagnosis MS, has

2016 Electronic physician

127. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. Full Text available with Trip Pro

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody that selectively depletes CD20+ B cells.In two identical phase 3 trials, we randomly assigned 821 and 835 patients with relapsing multiple sclerosis to receive intravenous ocrelizumab at a dose of 600 mg every 24 weeks or subcutaneous interferon beta-1a at a dose of 44 μg three times weekly for 96 weeks. The primary end (...) to 0.81; P<0.001), as was the percentage of patients with disability progression confirmed at 24 weeks (6.9% vs. 10.5%; hazard ratio, 0.60; 95% CI, 0.43 to 0.84; P=0.003). The mean number of gadolinium-enhancing lesions per T1-weighted magnetic resonance scan was 0.02 with ocrelizumab versus 0.29 with interferon beta-1a in trial 1 (94% lower number of lesions with ocrelizumab, P<0.001) and 0.02 versus 0.42 in trial 2 (95% lower number of lesions, P<0.001). The change in the Multiple Sclerosis

2016 NEJM Controlled trial quality: predicted high

128. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. Full Text available with Trip Pro

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. An evolving understanding of the immunopathogenesis of multiple sclerosis suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a humanized monoclonal antibody that selectively depletes CD20-expressing B cells, in the primary progressive form of the disease.In this phase 3 trial, we randomly assigned 732 patients with primary progressive multiple sclerosis in a 2:1 ratio to receive intravenous (...) of serious adverse events and serious infections.Among patients with primary progressive multiple sclerosis, ocrelizumab was associated with lower rates of clinical and MRI progression than placebo. Extended observation is required to determine the long-term safety and efficacy of ocrelizumab. (Funded by F. Hoffmann-La Roche; ORATORIO ClinicalTrials.gov number, NCT01194570 .).

2016 NEJM Controlled trial quality: predicted high

129. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort

Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal (...) multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort. Health Technology Assessment 2016; 20(81) Authors' objectives The ability to better predict disease progression represents a major unmet need in multiple sclerosis (MS), and would help to inform therapeutic and management choices. This study aims to develop multilevel models using longitudinal data on disease progression in patients with relapsing–remitting MS (RRMS

2016 Health Technology Assessment (HTA) Database.

130. Diagnosis of multiple sclerosis: progress and challenges. Full Text available with Trip Pro

Diagnosis of multiple sclerosis: progress and challenges. The diagnosis of multiple sclerosis is based on neurological symptoms and signs, alongside evidence of dissemination of CNS lesions in space and time. MRI is often sufficient to confirm the diagnosis when characteristic lesions accompany a typical clinical syndrome, but in some patients, further supportive information is obtained from cerebrospinal fluid examination and neurophysiological testing. Differentiation is important from other (...) diseases in which demyelination is a feature (eg, neuromyelitis optica spectrum disorder and acute disseminated encephalomyelitis) and from non-demyelinating disorders such as chronic small vessel disease and other inflammatory, granulomatous, infective, metabolic, and genetic causes that can mimic multiple sclerosis. Advances in MRI and serological and genetic testing have greatly increased accuracy in distinguishing multiple sclerosis from these disorders, but misdiagnosis can occur. In this Series

2016 Lancet

131. Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. Full Text available with Trip Pro

Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. Multiple sclerosis is a major cause of neurological disability, which accrues predominantly during progressive forms of the disease. Although development of multifocal inflammatory lesions is the underlying pathological process in relapsing-remitting multiple sclerosis, the gradual accumulation of disability that characterises progressive multiple sclerosis seems to result more from diffuse (...) immune mechanisms and neurodegeneration. As a result, the 14 anti-inflammatory drugs that have regulatory approval for treatment of relapsing-remitting multiple sclerosis have little or no efficacy in progressive multiple sclerosis without inflammatory lesion activity. Effective therapies for progressive multiple sclerosis that prevent worsening, reverse damage, and restore function are a major unmet need. In this Series paper we summarise the current status of therapy for progressive multiple

2016 Lancet

132. Evolving concepts in the treatment of relapsing multiple sclerosis. (Abstract)

Evolving concepts in the treatment of relapsing multiple sclerosis. In the past 20 years the treatment scenario of multiple sclerosis has radically changed. The increasing availability of effective disease-modifying therapies has shifted the aim of therapeutic interventions from a reduction in relapses and disability accrual, to the absence of any sign of clinical or MRI activity. The choice for therapy is increasingly complex and should be driven by an appropriate knowledge of the mechanisms

2016 Lancet

133. Disease modifying therapies for relapsing multiple sclerosis. (Abstract)

Disease modifying therapies for relapsing multiple sclerosis. Multiple sclerosis (MS) is a common, disabling, putatively autoimmune neurological disease with worldwide distribution. It typically begins as a relapsing disorder that later evolves to a secondary progressive phase. Inflammatory and neurodegenerative mechanisms seem to operate in both phases, but their relative contributions and interactions are incompletely understood. Disease modifying therapies (DMTs) approved for relapsing (...) multiple sclerosis interfere with a variety of immunological mechanisms to reduce rates of relapse, accumulation of disease burden measured by magnetic resonance imaging (MRI), and decline in neurological function over the two to three year duration of typical randomized controlled trials. Benefits of longer duration of therapy on disability are less clear, as data beyond three years are largely limited to observational studies. However, current DMTs do not slow accrual of disability once progressive

2016 BMJ

134. Daclizumab (Zinbryta) - multiple sclerosis

Daclizumab (Zinbryta) - multiple sclerosis Zinbryta (daclizumab) Injection U.S. Department of Health and Human Services Search FDA Submit search Zinbryta (daclizumab) Injection Zinbryta Company: Biogen Inc. Application No.: 761029 Approval Date: 05/27/2016 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: July 7, 2016 Vision

2016 FDA - Drug Approval Package

135. The Effectiveness of Group Cognitive Behavioral Therapy in Treating Obsessive-Compulsive Disorder in Women with Multiple Sclerosis (MS): A randomized double-blind controlled trial. Full Text available with Trip Pro

The Effectiveness of Group Cognitive Behavioral Therapy in Treating Obsessive-Compulsive Disorder in Women with Multiple Sclerosis (MS): A randomized double-blind controlled trial. Obsessive-compulsive disorder (OCD) is one of the most prevalent psychiatric disorders and can cause problems for individuals in all aspects of life, including social and personal dimensions.To study the effect of group cognitive-behavioral therapy on the reduction of OCD symptoms in female participants with multiple (...) sclerosis (MS).This double-blind randomized control trial was conducted from May 2012 to December 2014. The participants included 75 patients with MS who suffered from OCD and were referred to the Loghman Hakim and Imam Khomeini hospitals in Tehran, Iran. Thirty participants had been diagnosed through Yale-Brown Obsessive-Compulsive Symptoms (Y-BOCS). The participants were randomly divided into an experimental group (n=15) and a control group (n=15). Eleven sessions of cognitive-behavioral therapy were

2016 Electronic physician Controlled trial quality: uncertain

136. Delta-9-tetrahydrocannabinol/Cannabidiol for Spasticity in Multiple Sclerosis: Clinical Effectiveness and Guidelines

Delta-9-tetrahydrocannabinol/Cannabidiol for Spasticity in Multiple Sclerosis: Clinical Effectiveness and Guidelines Delta-9-tetrahydrocannabinol/Cannabidiol for Spasticity in Multiple Sclerosis: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Delta-9-tetrahydrocannabinol/Cannabidiol for Spasticity in Multiple Sclerosis: Clinical Effectiveness and Guidelines Delta-9-tetrahydrocannabinol/Cannabidiol for Spasticity in Multiple Sclerosis: Clinical Effectiveness (...) and Guidelines Published on: May 4, 2016 Project Number: RB0983-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question 1. What is the clinical effectiveness of delta-9-tetrahydrocannabinol/cannabidiol for the treatment of spasticity in patients with Multiple Sclerosis? 2. What are the evidence-based guidelines associated with delta-9-tetrahydrocannabinol/cannabidiol for the treatment of spasticity in patients with Multiple Sclerosis? Key Message Three systematic

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

137. Modifiable Risk Factors in the Progression of Multiple Sclerosis

Modifiable Risk Factors in the Progression of Multiple Sclerosis Management Briefs eBrief-no111 -- Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs eBrief-no111 -- Health Services Research & Development Management eBrief no. 111 » Issue 111 April 2016 The report is a product of the VA/HSR&D Evidence Synthesis Program. Systematic Review: Modifiable Risk Factors in the Progression (...) of Multiple Sclerosis Multiple sclerosis (MS) is the most common progressive disease of the central nervous system in young adults and the cause of serious physical disability in adults of working age. MS disease presentation is very heterogeneous with variable clinical manifestations that evolve over time. In about 50 percent of patients the course of MS changes from relapsing-remitting to secondary progressive disease after ten years. Relapsing-remitting disease manifests in relapses followed by periods

2016 Veterans Affairs - R&D

138. Evaluation of KIR4.1 as an Immune Target in Multiple Sclerosis. Full Text available with Trip Pro

Evaluation of KIR4.1 as an Immune Target in Multiple Sclerosis. 27074083 2016 04 25 2018 11 13 1533-4406 374 15 2016 Apr 14 The New England journal of medicine N. Engl. J. Med. Evaluation of KIR4.1 as an Immune Target in Multiple Sclerosis. 1495-6 10.1056/NEJMc1513302 Chastre Anne A Yale School of Medicine, New Haven, CT kevin.oconnor@yale.edu. Hafler David A DA Yale School of Medicine, New Haven, CT kevin.oconnor@yale.edu. O'Connor Kevin C KC Yale School of Medicine, New Haven, CT (...) NIH HHS United States U19 AI046130 AI NIAID NIH HHS United States GM093080 GM NIGMS NIH HHS United States Letter Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't United States N Engl J Med 0255562 0028-4793 0 Antibodies, Monoclonal 0 Autoantibodies 0 Biomarkers 0 Kcnj10 (channel) 0 Potassium Channels, Inwardly Rectifying AIM IM Antibodies, Monoclonal Autoantibodies blood Biomarkers blood Case-Control Studies Enzyme-Linked Immunosorbent Assay Humans Multiple Sclerosis diagnosis

2016 NEJM

139. Multiple Sclerosis and Antibodies against KIR4.1. (Abstract)

Multiple Sclerosis and Antibodies against KIR4.1. 27074084 2016 04 25 2016 04 14 1533-4406 374 15 2016 Apr 14 The New England journal of medicine N. Engl. J. Med. Multiple Sclerosis and Antibodies against KIR4.1. 1496-8 10.1056/NEJMc1507131 Pröbstel Anne-Katrin AK University Hospital Basel, Basel, Switzerland tobias.derfuss@usb.ch. Kuhle Jens J University Hospital Basel, Basel, Switzerland tobias.derfuss@usb.ch. Lecourt Anne-Catherine AC University Hospital Basel, Basel, Switzerland (...) Rectifying AIM IM Autoantibodies blood Biomarkers blood Blotting, Western Case-Control Studies Enzyme-Linked Immunosorbent Assay Humans Multiple Sclerosis diagnosis immunology Potassium Channels, Inwardly Rectifying immunology 2016 4 14 6 0 2016 4 14 6 0 2016 4 26 6 0 ppublish 27074084 10.1056/NEJMc1507131

2016 NEJM

140. Teriflunomide for multiple sclerosis. (Abstract)

Teriflunomide for multiple sclerosis. This is an update of the Cochrane review "Teriflunomide for multiple sclerosis" (first published in The Cochrane Library 2012, Issue 12).Multiple sclerosis (MS) is a chronic immune-mediated disease of the central nervous system. It is clinically characterized by recurrent relapses or progression, or both, often leading to severe neurological disability and a serious decline in quality of life. Disease-modifying therapies (DMTs) for MS aim to prevent (...) , fingolimod, dimethyl fumarate, alemtuzumab) for modifying the disease course in people with MS.We searched the Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group Specialised Trials Register (30 September 2015). We checked reference lists of published reviews and retrieved articles and searched reports (2004 to September 2015) from the MS societies in Europe and America. We also communicated with investigators participating in trials of teriflunomide and the pharmaceutical company, Sanofi

2016 Cochrane